FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Federal Register

Draft Guide on Deemed to be a License BLAs

Federal Register notice: FDA announces the availability of a draft guidance entitled The Deemed to be a License Provision of the BPCI Act: Questions a...

Human Drugs

CGMP Integrity and Compliance Q&A Guidance

FDA issues a question-and-answer guidance on data integrity and compliance with drug CGMPs.

Medical Devices

Guidance on PMA, BLA User Fees and Refunds

FDA issues a guidance explaining user fees and refunds for PMAs and some device BLAs as outlined in the MDUFA 4 agreement.

Human Drugs

Dont Use 2 HelloCig E-Liquids: FDA

FDA cautions consumers that two HelloCig e-liquids illegally contain undeclared prescription drug active ingredients used to treat erectile dysfunctio...

Human Drugs

U.S. Should OK Discovery in FCA Materiality Cases: Analysis

Three Fried Frank attorneys say the Justice Department must allow discovery on False Claims Act questions of materiality if the government wants the f...

Human Drugs

Imvexxy Bioquivalence Guidance Sought

TherapeuticsMD asks FDA to issue a product-specific bioequivalence guidance for its Imvexxy estradiol product.

Human Drugs

Intra-Cellular NDA Accepted for Schizophrenia Drug

FDA accepts an Intra-Cellular Therapies NDA for lumateperone, an investigational agent for treating schizophrenia.

Human Drugs

Complete Response for SpecGx Pain Drug

FDA issues Mallinckrodt subsidiary SpecGx a complete response letter on its NDA for its investigational abuse-deterrent, immediate-release reformulati...

Human Drugs

Support for Hemophilia Gene Therapy Guidance

Three stakeholders generally praise FDA for its draft guidance on developing human gene therapy products to treat hemophilia.

Human Drugs

ORA Issues 40% More Drug Warning Letters in FY 2018

FDAs Office of Regulatory Affairs steps up its Warning Letter issuance to pharmaceutical firms in fiscal year 2018, issuing 40% more letters.